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Abstract ErbB receptors (EGFR (ErbB1), ErbB2, ErbB3,
and ErbB4) are important regulators of normal growth and
diVerentiation, and they are involved in the pathogenesis of
cancer. Following ligand binding and receptor activation,
EGFR is endocytosed and transported to lysosomes where
the receptor is degraded. This downregulation of EGFR is a
complex and tightly regulated process. The functions of
ErbB2, ErbB3, and ErbB4 are also regulated by endocytosis
to some extent, although the current knowledge of these pro-
cesses is sparse. Impaired endocytic downregulation of sig-
naling receptors is frequently associated with cancer, since it
can lead to increased and uncontrolled receptor signaling. In
this review we describe the current knowledge of ErbB
receptor endocytic downregulation. In addition, we outline
how ErbB receptors can escape endocytic downregulation in
cancer, and we discuss how targeted anti-cancer therapy
may induce endocytic downregulation of ErbB receptors.
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Introduction
Proper endocytic uptake and endosomal sorting of signal-
ing receptors are crucial mechanisms for the regulation of
signaling activity involved in cellular growth, development,
and diVerentiation (Crosetto et al. 2005; Fischer et al. 2006;
Giebel and Wodarz 2006; Le Borgne 2006; Polo and Di
Fiore 2006; Sorkin and von Zastrow 2002). This is not least
true for the epidermal growth factor receptor (EGFR), a
member of the ErbB family of receptor tyrosine kinases
which contains four members: EGFR (ErbB1), ErbB2,
ErbB3 and ErbB4. In addition to playing an important role
in normal cellular functions, these receptors are involved in
the pathogenesis of human cancers and receive much atten-
tion as targets for development of new anti-cancer drugs
(Hynes and Lane 2005). There are several mechanisms
whereby cancer cells can obtain uncontrolled ErbB receptor
signaling, including increased receptor expression, activating
mutations, and escape of endocytic receptor downregu-
lation (Bache et al. 2004; Citri and Yarden 2006; Norm-
anno et al. 2005; Polo et al. 2004; Warren and Landgraf
2006).
Our current understanding of endocytic downregulation
of ErbB receptors is largely based on knowledge of EGFR
behavior upon binding of epidermal growth factor (EGF)
(Bache et al. 2004; Dikic 2003; Gruenberg and Stenmark
2004). EGFR is among the most well studied receptors, and
it is regarded as a prototype of a signaling receptor that is
internalized and degraded following ligand binding. In con-
trast, surprisingly little is known about endocytosis of
ErbB2-4 as well as about EGFR endocytosis following
binding of ligands other than EGF. However, it is becoming
increasingly clear that the other ErbB receptors do not
behave like EGFR regarding endocytosis. In this review we
outline the molecular mechanisms of EGF-induced endo-
cytic downregulation of EGFR. In addition, we describe the
current knowledge of internalization and downregulation of
the other ErbB receptors and discuss how the various ErbB
ligands diVer in their potential to induce receptor
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downregulation. Finally, we focus on internalization of
these receptors as a promising target in anti-cancer therapy.
The ErbB receptor system
A thorough description of the structure and biological func-
tions of the four ErbB receptors and their ligands is beyond
the scope of this review and can be found elsewhere (Citri
and Yarden 2006; Hynes and Lane 2005; Jones et al. 2006).
In brief, the ErbB receptors are transmembrane receptor
tyrosine kinases consisting of a glycosylated, extracellular
N-terminal part containing a ligand binding site and a
dimerization arm, a transmembrane segment, and an intra-
cellular part containing a tyrosine kinase domain and a
C-terminal tail with several phosphorylation sites (Fig. 1)
(Normanno et al. 2005). A large number of ErbB ligands
have been identiWed, some of which can bind to more than
one of the ErbB receptors with high aYnity (Table 1)
(Breuleux  2007; Harris et al. 2003). The active, ligand-
bound ErbB receptors function as homo- or heterodimers,
which can activate a multitude of signaling pathways
involved in proliferation, diVerentiation, cell survival, and
migration (Normanno et al. 2005).
ErbB receptor activation
The initial steps of ligand-mediated ErbB receptor activa-
tion have been well described upon solving the crystal
structure of the EGFR extracellular domain bound to EGF
(Garrett et al. 2002; Ogiso et al. 2002). EGF binding to
EGFR has been proposed to induce a conformational
change exposing the dimerization arm in the receptor extra-
cellular domain (Burgess et al. 2003; Ferguson et al. 2003;
Ogiso et al. 2002). Upon dimerization, the receptor’s intrin-
sic kinase activity cross-phosphorylates speciWc residues in
the C-terminal tail of the partnering receptor, allowing for
the recruitment of phosphotyrosine-binding proteins to
EGFR. ErbB3 and ErbB4 dimerize in response to ligand
binding in a manner similar to EGFR, whereas ErbB2
diVers from the other ErbB receptors by not binding to any
ligand with high aYnity (Bouyain et al. 2005; Burgess et al.
2003; Kani et al. 2005). Instead, ErbB2 is in a constitu-
tively active conformation with an exposed dimerization
arm even in the absence of ligand (Burgess et al. 2003). Its
ability to homodimerize is limited due to the electronega-
tivity of its extracellular part, but ErbB2 is the preferred
Fig. 1 Structure of EGFR. In the extracellular part of the receptor,
EGFR harbours two domains (L1 and L2) that upon folding form the
ligand-binding pocket. Between L1 and L2 is another domain (S1) that
includes the dimerization arm. Intracellularly, EGFR has a kinase
domain and a C-terminal tail with several amino acid residues that can
be phosphorylated. The tyrosine residues (Y) that are involved in Cbl
binding are shown. The parts of wild-type EGFR that are deleted in
EGFRvIII, EGFRvIV, and EGFRvV are indicated
Table 1 ErbB receptors and their ligands
Receptor Remarks Ligands
EGFR 
(ErbB1)
Epidermal growth 
factor (EGF) 
Transforming growth 
factor  (TGF)
Heparin-binding 
EGF (HB-EGF)
-Cellulin
Amphiregulin
Epiregulin
Epigen
ErbB2 Constitutively exposed 
dimerization arm
ErbB3 Kinase dead Heregulin-1/Neuregulin-1
Heregulin-2/Neuregulin-2
ErbB4 Heregulin-1/Neuregulin-1
Heregulin-2/Neuregulin-2
Heregulin-3/Neuregulin-3
Heregulin-4/Neuregulin-4
Heparin-binding 
EGF (HB-EGF)
-Cellulin
EpiregulinHistochem Cell Biol (2008) 129:563–578 565
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heterodimerization partner for the other ErbB receptors
(Garrett et al. 2003; Graus-Porta et al. 1997; Tzahar et al.
1996).
The signal transduction pathways activated by ErbB
receptors include well-known signaling cascades such as
the Ras-Erk1/2 pathway, the phospholipase C-protein
kinase C pathway, the phosphatidyl inositol 3 (PI 3)-
kinase-Akt pathway, and STAT signaling.
Endocytic downregulation of signaling receptors has for
many years been regarded solely as a means of attenuating
receptor signaling. However, during the last decade an
increasing amount of evidence has suggested that some
receptors, including EGFR, may continue their signaling
activity from endocytic compartments and that the signal-
ing occurring from here is qualitatively diVerent from the
signaling taking place at the plasma membrane (Mia-
czynska et al. 2004). Thus, ErbB receptor endocytosis is
not merely a means of turning oV activated receptors; it
may also be a regulatory mechanism altering the signaling
outcome.
Endocytic downregulation of EGFR
Regarding ligand-induced endocytic receptor downregula-
tion, EGFR has been the most popular model system for
many years, and the mechanisms of EGFR endocytosis and
intracellular traYcking are therefore relatively well under-
stood.
EGFR is activated upon EGF binding, leading to signal-
ing and relocation to invaginating clathrin-coated pits
(CCPs) on the plasma membrane. These pits give rise to
clathrin-coated endocytic vesicles, and after the coat has
been released from the membrane, the vesicles fuse with
early endosomes and thereby deliver the receptor to this
compartment. Here the receptor is sorted for further trans-
port, either back to the cell surface by recycling, or to intra-
luminal vesicles (ILVs), a pathway that eventually leads to
delivery of EGFR to lysosomes for degradation (Fig. 2).
Some of these steps are now well established, but others
remain elusive. Below we describe both what is known and
what challenges we are facing in understanding the crucial
pathway of clathrin-mediated EGFR endocytosis and endo-
somal sorting.
Sorting of EGFR to clathrin coated pits: ubiquitination
or not?
One of the Wrst steps in clathrin-mediated endocytic down-
regulation is the transport of cargo into CCPs. Despite the
importance of regulating whether EGFR is endocytosed,
the molecular machinery controlling this is poorly under-
stood.
The constitutively endocytosed receptors, the transferrin
receptor and the low-density lipoprotein receptor, are sorted
into CCPs by interaction with the clathrin-binding AP-2
complex through conserved tyrosine-based motifs in the
receptor’s intracellular tail. EGFR also interacts with AP-2,
indicating a similar role of AP-2 in EGFR endocytosis
(Sorkin et al. 1995; Sorkin and Carpenter 1993). However,
EGFR is not sorted into CCPs in its resting state, and the
direct interaction of AP-2 with EGFR does not seem to be
necessary for EGFR internalization (Nesterov et al. 1995).
Thus, additional interaction partners in the CCPs are
required for EGFR to be sorted into these plasma mem-
brane microdomains. Since the kinase activity of EGFR has
been shown to be important for this sorting (Lamaze and
Schmid 1995), such interaction partners should bind modi-
Wcations of EGFR that are only present in the activated
state; e.g. phosphorylated residues and/or ubiquitinated res-
idues.
Ubiquitination (Text box 1) has been known to mediate
endocytosis of membrane receptors for vacuolar degrada-
tion in yeast (Hicke and Riezman 1996; Kolling and Hol-
lenberg 1994), and ubiquitination has also been found to be
involved in endocytic downregulation of mammalian
receptors such as EGFR (reviewed in (Hicke 1999)). As a
result, ubiquitination has long been considered a likely can-
didate as a CCP targeting signal at the plasma membrane.
Upon activation of EGFR, it is heavily ubiquitinated by
the attachment of both monoubiquitin and polyubiquitin
(Text box 1). As will be discussed below, this ubiquitina-
tion is a prerequisite for endosomal sorting of EGFR to
ILVs in multivesicular bodies (MVBs), but its importance
in the initial sorting to CCPs and internalization from the
plasma membrane has been the subject of controversy for
Text box 1 Ubiquitination566 Histochem Cell Biol (2008) 129:563–578
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some time. The ubiquitin ligase responsible for EGFR
ubiquitination is Cbl, a ring-Wnger domain E3 ubiquitin
ligase (Levkowitz et al. 1999). Cbl is indeed necessary for
EGFR endocytosis (Jiang and Sorkin 2003). Cbl can bind
EGFR either directly by binding to phosphorylated Y1045,
or indirectly via the adaptor protein Grb2, which binds to
phosphorylated Y1068 and Y1086 (Fig. 1) (Levkowitz
et al.  1999; Waterman et al. 2002). Binding of Cbl via
phosphorylated Y1045 is not necessary for EGFR endo-
cytosis, since the Y1045F EGFR mutant that cannot bind Cbl
directly is internalized almost as eYciently as wild-type
EGFR (Grøvdal et al. 2004; Jiang et al. 2003). In contrast,
Cbl binding to EGFR via Grb2 is necessary for receptor
internalization (Huang and Sorkin 2005). Thus, Grb2
knockdown inhibits EGFR endocytosis, but a chimeric pro-
tein consisting of the Y1068/Y1086-binding domain of
Grb2 fused to Cbl can rescue EGFR internalization in Grb2
depleted cells, showing that the prime role of Grb2 in
EGFR internalization is recruitment of Cbl (Huang and
Sorkin 2005).
Since functional Cbl is a prerequisite for EGFR internali-
zation (Jiang and Sorkin 2003), and Cbl ubiquitinates
EGFR (Levkowitz et al. 1998), it has long been assumed
that Cbl-mediated ubiquitination of EGFR is the prime sig-
nal for EGFR translocation to CCPs. In accordance with
this, overexpression of the Cbl mutant 70Z-Cbl with
impaired ubiquitin ligase activity inhibits EGFR internali-
zation (Jiang and Sorkin 2003). To further investigate the
Fig. 2 Internalization and endosomal sorting of EGFR. Main Wgure:
upon activation, EGFR (green) is translocated to clathrin coated pits
(CCP) on the plasma membrane and internalized (grey arrows). After
transport to early endosomes (EE), EGFR is either recycled back to the
plasma membrane (white arrows) or taken up into intraluminal vesi-
cles (ILVs). EE will mature to late endosomes (LE), and EGFR in ILVs
will eventually be degraded in lysosomes (Lys) (black arrows). Upper
insert at the plasma membrane, EGF-activated EGFR dimerize and the
kinase activity of the receptors phosphorylates tyrosine residues (P) in
EGFR. This creates docking sites for intracellular proteins such as
Grb2. Grb2 mediates binding of the ubiquitin ligase Cbl that adds
mono- or polyubiquitins (Ub) to EGFR. Activated EGFR is transported
to clathrin coated pits that in addition to clathrin also consists of Eps15
and other proteins. Lower insert At the EE vacuolar membrane, EGFR
destined for degradation still binds Cbl and is continuously phosphor-
ylated and ubiquitinated. The EGFR ubiquitins are bound by Hrs that
resides in at Hrs/STAM/clathrin coat, and this is followed by binding
of ESCRT complexes to the ubiquitinated EGFR leading to uptake into
ILVsHistochem Cell Biol (2008) 129:563–578 567
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role of EGFR ubiquitination in internalization, an EGFR
mutated on 15 lysine residues was recently constructed.
This mutant had an ubiquitination level corresponding to
1% of that seen for wild-type EGFR after EGF stimulation.
Interestingly, the mutated EGFR still retained full kinase
activity and displayed normal internalization (Huang et al.
2007). This could imply that EGFR ubiquitination is not a
signal for internalization. Alternatively, the endocytic
machinery recognizing ubiquitinated EGFR is highly sensi-
tive, so that even a 1% residual ubiquitination is suYcient
for proper targeting of EGFR to CCPs.
Importantly, Cbl may serve other functions in addition to
ubiquitin ligase activity. It has been reported that Cbl binds
endophilin via CIN85 (Soubeyran et al. 2002). Endophilin
is a known regulator of clathrin-mediated endocytosis
(Reutens and Begley 2002), and this recruitment of CIN85
and endophilin to EGFR by Cbl has been shown to be
important for EGFR internalization (Soubeyran et al.
2002).
Although the role of EGFR ubiquitination as an internali-
zation signal is controversial, several candidates, including
Eps15, have been suggested as adaptors for sorting ubiqui-
tinated EGFR into CCPs. Eps15 is found in CCPs and has
an ubiquitin-binding domain (Hawryluk et al. 2006; Stang
et al. 2004). Furthermore, Eps15 is recruited to the plasma
membrane upon EGF stimulation of EGFR (Stang et al.
2004; Torrisi et al. 1999), and expression of dominant-nega-
tive Eps15 as well as siRNA-mediated knockdown of
Eps15 has been shown to inhibit EGFR endocytosis
(Bakowska et al. 2007; Benmerah et al. 1998; Fallon et al.
2006). Phosphorylation of Eps15 has also been shown to be
necessary for EGFR internalization (Confalonieri et al.
2000). However, a direct evidence of Eps15 as an adaptor
protein recognizing ubiquitinated EGFR via interactions
with EGFR-attached ubiquitin has so far not been pre-
sented.
At present, it remains obscure which mechanisms are
responsible for sorting of the activated EGFR to coated
pits, although it is clear that Cbl and Grb2 are central, and
Eps15 may have important functions. One possible expla-
nation for the apparent contradictory results regarding
ubiquitin as an endocytic signal for EGFR is that it is not
ubiquitination of EGFR itself but rather ubiquitination of
accessory proteins by Cbl that is necessary for EGFR inter-
nalization.
Endosomal sorting of EGFR: a key role of ubiquitination
Upon internalization by clathrin-mediated endocytosis,
EGFR is transported to early endosomes (Fig. 2). Both
cargo destined for lysosomal degradation and for recycling
back to the plasma membrane is delivered here, and the
compartment is sometimes seen in the electron microscope
as a vacuole with tubular elongations. The tubular elon-
gated parts of the early endosomes are believed to be
involved in recycling, whereas sorting for degradation initi-
ates at the vacuolar membrane of the endosomes by inward
budding, giving rise to ILVs containing membrane proteins
destined for lysosomal degradation (Fig. 2). The internalized
EGFR can be sorted both for recycling and for lysosomal
degradation. Whereas recycling seems to be the default
pathway from early endosomes, sorting for lysosomal
degradation is mediated by Hrs/STAM and by the
endosomal sorting complex required for transport (ESCRT)
complexes (ESCRT-I to -III) that are believed to mediate
receptor translocation into ILVs of MVBs (for recent
review see (Williams and Urbe 2007)).
The EGF-activated EGFR is also associated with Cbl in
early endosomes, resulting in continued ubiquitination of
EGFR (Duan et al. 2003; Longva et al. 2002). Contrary to
its uncertain role in receptor internalization (see above),
ubiquitination has been convincingly demonstrated to be
important for endosomal sorting of EGFR to lysosomes.
EGFR mutated at intracellular lysine residues to give a
receptor with decreased ubiquitination is severely degrada-
tion impaired following EGF stimulation (Huang 2006,
2007). Likewise, the Y1045F EGFR mutant that does not
bind directly to Cbl and displays reduced ubiquitination is
degradation impaired (Grøvdal et al. 2004; Jiang and Sor-
kin  2003; Levkowitz et al. 1999). This mutant does not
translocate to ILVs (Grøvdal et al. 2004), giving further
support to a model where ubiquitin is the signal for EGFR
sorting for degradation.
Ubiquitin chains are recognized by ESCRT complexes,
which retain ubiquitinated cargo in the membrane of early
endosomes thereby hindering receptor recycling (Fig. 2)
(Raiborg and Stenmark 2002). The Wrst described point of
recognition is Hrs and STAM, also known as the ESCRT-0
complex. On early endosomes, Hrs and clathrin form
dynamic microdomains, which can be seen by EM as Xat
electron-dense areas on the limiting membrane (Raiborg
et al.  2001; Sachse et al. 2002). Hrs and STAM interact
with ubiquitinated cargo via their ubiquitin-interacting
motif (UIM) domains. The proteins preferentially bind
polyubiquitin (Polo et al. 2002), and the UIM of Hrs has
recently been shown to bind two ubiquitin molecules simul-
taneously (Hirano et al. 2006). Conceivably, cargo must be
either polyubiquitinated by K63-linked polyubiquitin
chains or multiply monoubiquitinated for eYcient sorting
towards the lysosome for degradation (Barriere et al. 2007).
This is in concordance with more than 50% of EGFR
ubiquitination being in the form of poly-ubiquitin chains,
primarily via K63 (Text box 1) (Huang et al. 2006).
After Hrs/STAM has retained ubiquitinated cargo within
microdomains in the vacuolar membrane of the early endo-
some, ESCRT complexes (ESCRT-I–ESCRT-III) are568 Histochem Cell Biol (2008) 129:563–578
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sequentially recruited, eventually leading to sorting of
EGFR into ILVs (reviewed in (Williams and Urbe 2007)).
Recently, siRNA studies showed that knock-down of Hrs
or ESCRT-I components caused increased recycling of
EGFR. In contrast, knockdown of ESCRT-II and ESCRT-
III components did not result in increased recycling of
EGFR, but did impair degradation (Raiborg et al. 2007).
This indicates that the fate of EGFR (recycling versus degra-
dation) is determined upstream of ESCRT-II. ESCRT-II
appears to be necessary for sorting of EGFR to ILVs. In
contrast, the exact function of the ESCRT-III complex in
EGFR sorting seems to be more complex. The original
model was that ESCRT-III is important for formation of
ILVs (Williams and Urbe 2007). However, it was recently
reported that upon depletion of the ESCRT-III component
VPS24, EGFR is still sorted into ILVs in MVBs and
silenced (Bache et al. 2006). Thus the ESCRT-III complex
might function downstream of internalization to ILVs, per-
haps as late as in MVB fusion with lysosomes (Bache et al.
2006).
DiVerential eVects of EGFR ligands on EGFR degradation
The model for EGFR sorting to lysosomes described above
has been developed based on studies of EGF-stimulated
cells. Six other ligands for EGFR have been described
(Table 1), all of which play important roles both during
embryogenesis and in adult life. In addition, EGFR ligands
have been found in high concentrations in human cancers
(Normanno et al. 2001; Normanno et al. 2005; Revillion
et al. 2008). It is therefore important to establish whether
the additional ligands have the same eVects on EGFR
downregulation as EGF. The only other EGFR ligand that
has been well investigated with respect to EGFR traYcking
is transforming growth factor  (TGF). Whereas EGF tar-
gets EGFR to the degradative pathway, TGF allows recep-
tor recycling (Decker 1990). The diVerential intracellular
sorting of EGFR after stimulation with TGF compared to
EGF is caused by diVerences in the pH-dependence of
receptor-ligand binding. Whereas EGF binding to EGFR is
relatively stable at the lower pH in endosomes, TGF dis-
sociates from the receptor at endosomal pH (Ebner and
Derynck 1991). It is believed that continuous ligand bind-
ing is necessary for continuous ubiquitination and thereby
for translocation of EGFR to the ILVs. In case of TGF, the
ligand rapidly dissociates from the receptor in endosomes,
leading to receptor dephosphorylation, de-ubiquitination,
and recycling to the cell surface (Longva et al. 2002). Inter-
estingly, this diVerence in their potential to induce EGFR
degradation is thought to be the main reason why TGF is a
stronger mitogen than EGF (Waterman et al. 1998).
At present, the eVects of heparin-binding EGF (HB-
EGF), -cellulin, Epiregulin, and Epigen on EGFR traYck-
ing has not been investigated. A single study has investi-
gated the eVect of Amphiregulin on endocytic EGFR
downregulation, and found that Amphiregulin failed to
induce EGFR degradation. This was the case even in cells
overexpressing Cbl, although in these cells EGFR was
highly ubiquitinated following Amphiregulin stimulation
(Stern et al. 2007). Interestingly, this suggests that pro-
nounced receptor ubiquitination is not suYcient to target
receptors for lysosomal degradation. More studies are war-
ranted to uncover how the remaining EGFR ligands aVect
receptor ubiquitination, endocytosis, and lysosomal degra-
dation.
Clathrin-independent endocytic mechanisms involved
in EGFR uptake
Although clathrin-dependent endocytosis is generally con-
sidered to be the major mechanism for internalization and
downregulation of EGFR, other endocytic pathways have
also been proposed during recent years, especially follow-
ing stimulation with high concentrations of EGF (Sigis-
mund et al. 2005). The concentration of EGF varies greatly
throughout the human body. Thus, while the EGF concen-
tration in tissue Xuid is about 1–2 ng/ml, it is much higher,
up to 100 ng/ml or more, in tubular duct lumens of e.g., the
kidney, salivary glands, and the mammary gland (Carpenter
and Cohen 1979; Hayashi and Sakamoto 1988). Normally,
EGFR is not reached by the high luminal concentrations of
EGF in these systems, since the receptor is present at the
basolateral site of the epithelial cells. However, during
wound healing or malignant transformation the tight junc-
tions disappear and allow the high concentrations of EGF to
get access to the receptor (Mullin 2004). Very high EGF
concentration can also be found in solid tumors (Salomon
et al. 1995). It is therefore relevant to study whether the
mechanisms of endocytic downregulation of EGFR are
aVected by the concentration of stimulating ligand.
Sigismund et al. (2005) have reported a role of caveolae
in EGFR uptake. They found that at low concentrations of
EGF (1–2 ng/ml), EGFR was not ubiquitinated and became
internalized by clathrin-dependent endocytosis. In contrast,
at high concentrations of EGF (20 ng/ml) the receptor
became ubiquitinated and was to a high degree internalized
by caveolae. This conclusion was based upon immunogold
labeling electron microscopy showing that at 20 ng/ml of
EGF, about half of the receptors were localized to caveolae
and to caveolae-like structures or “caveosomes” apparently
not connected to the plasma membrane (Sigismund et al.
2005). However, it is likely that such caveolae-like struc-
tures that appear to be freely located in the cytoplasm are
actually surface-connected in another plane of sectioning
(Sandvig et al. 2008). In another study, Orlichenko et al.
(2006) showed that incubation of epithelial cells withHistochem Cell Biol (2008) 129:563–578 569
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30 ng/ml of EGF for 5–20 min resulted in an eight to ten-
fold increase in the number of plasma membrane caveolae
due to EGF-induced tyrosine phosphorylation of caveolin-
1. Moreover, live cell imaging revealed increased dynamics
of green Xuorescent protein (GFP)-tagged caveolin upon
stimulation of cells with 30 ng/ml EGF. After 15–20 min of
treatment, Xuorescent caveolae were seen to move from the
plasma membrane deeper into the cytoplasm (Orlichenko
et al. 2006). Thus, some studies suggest a role of caveolae
in EGFR endocytosis.
Caveolae are quite immobile under normal, nonstimu-
lated conditions as revealed by FRAP (Fluorescence
Recovery After Photobleaching) analysis of cells transfec-
ted with GFP-tagged caveolin and by other approaches
(Hommelgaard et al. 2005; Kirkham et al. 2005; Thomsen
et al. 2002). If caveolae were involved in EGFR-internali-
zation stimulated by high concentrations of EGF to any sig-
niWcant degree, two possible mechanisms can be
envisioned: either the EGFR-containing caveolae become
internalized in a single-wave process, leading to depletion
of the plasma membrane for caveolae as has been reported
for SV40 virus (Pelkmans et al. 2001, 2002), or activation
of EGFR stimulates an increased mobility or turnover of
caveolae so that internalized caveolae become replaced by
new caveolae at the plasma membrane. These scenarios
have been tested by live cell imaging of cells expressing
GFP- tagged caveolin (Kazazic et al. 2006). It was shown
that even 100 ng/ml of EGF did not cause any wave of
internalized caveolae from the plasma membrane, or any
increased turnover of caveolae at the plasma membrane.
Moreover, it was found that inhibition of clathrin-mediated
endocytosis by siRNA against clathrin heavy chain strongly
inhibited internalization of EGF both at 1 and 60 ng/ml
EGF. It was therefore concluded that clathrin-dependent
endocytosis is the major pathway for EGFR uptake also at
high EGF concentrations, and that caveolae do not contrib-
ute signiWcantly to endocytosis of EGFR at any EGF con-
centrations (Kazazic et al. 2006).
At high concentrations of EGF (100 ng/ml), induction of
ruZing and macropinocytosis can be observed in some
cells (Fig. 3, K. RoepstorV, unpublished observations).
However, whether ligand and receptor internalization in
this way leads to lysosomal degradation is uncertain. Fur-
thermore, Orth et al. (2006) found that EGF (30 ng/ml)
stimulated the formation of dorsal, circular waves which
progressed inward and resulted in sequestration of about
50% of the activated EGFR from the plasma membrane.
The process resulted in the formation of EGFR-positive
tubular structures, and it was dependent on actin reorgani-
zation, receptor phosphorylation, PI 3-kinase activity, and
dynamin 2. The functional consequences of the process
remain to be determined, but the dorsal wave formation
seems to be less frequent in tumor cells than in normal cells
(Orth et al. 2006).
In conclusion, although alternative clathrin-independent
mechanisms of EGFR endocytosis have been suggested,
clathrin-mediated endocytosis still appear to be by far the
most important mechanism for EGFR downregulation.
Endocytic downregulation of ErbB2
Interestingly, the behaviour of ErbB2 regarding endocytic
downregulation diVers signiWcantly from that of EGFR, and
it is generally accepted that ErbB2 avoids eYcient endo-
cytic downregulation (Austin et al. 2004; Baulida et al.
1996; Hommelgaard et al. 2004; Longva et al. 2005; Sorkin
and Carpenter 1993; Wang et al. 1999).
Several studies have investigated why ErbB2 is less sus-
ceptible to endocytic downregulation than EGFR after acti-
vation, and two fundamentally diVerent cellular
mechanisms could explain this: ineYcient internalization
(Baulida et al. 1996; Hommelgaard et al. 2004; Lerdrup
et al. 2006; Longva et al. 2005; Sorkin and Carpenter 1993;
Wang et al. 1999), or eYcient recycling of endocytosed
ErbB2 back to the plasma membrane (Austin et al. 2004;
Citri et al. 2003; Hendriks et al. 2003a,  2003b; Klapper
et al.  2000; Lenferink et al. 1998; Yarden 2001). Using
antibodies labeled with Xuorophores or gold-particles to
monitor ErbB2 traYcking, Austin and co-workers found
that ErbB2 is constantly internalized and recycled (Austin
et al. 2004). In contrast, two studies found no observable
intracellular ErbB2 in unstimulated cells and that treatment
with monensin, a compound known to inhibit recycling, led
to very little intracellular accumulation of ErbB2 within
two hours (Lerdrup et al. 2006; Longva et al. 2005). Impor-
tantly, immunogold labeling electron microscopy has dem-
onstrated that ErbB2 is very infrequently found in clathrin
coated pits: as little as 1 of 10,000 labeled ErbB2 molecules
localize to these structures in unstimulated cells or in cells
treated with ErbB ligands (Fig. 4a) (Hommelgaard et al.
2004). This suggests that the ineYcient downregulation of
ErbB2 is due to a low basal rate of internalization, although
it is possible that ErbB2 could be taken up by clathrin inde-
pendent endocytosis.
A chimeric EGFR where the C-terminal tail has been
replaced by that of ErbB2 is as endocytosis impaired as a
chimeric EGFR where the entire intracellular part has been
replaced by that of ErbB2 (Sorkin and Carpenter 1993).
This suggests that the C-terminal tail of ErbB2 is responsi-
ble for its endocytic impairment, and an interesting hypo-
thesis is that this is caused by an inhibitory signal rather than a
lack of endocytic stimuli (Sorkin and Carpenter 1993). This
is supported by the lower stability and increased endocytic570 Histochem Cell Biol (2008) 129:563–578
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downregulation of ErbB2 deletion mutants, which lack the
C-terminal tail, compared to full-length ErbB2 (Lerdrup
et al.  2007; Tikhomirov and Carpenter 2003). As men-
tioned previously, phosphorylation of EGFR on Y1045 is
important for recruitment of Cbl and endocytic downregu-
lation of EGFR. A Cbl docking site is also present in ErbB2
(Klapper et al. 2000; Levkowitz et al. 1999), and Cbl can
be recruited to ErbB2 (Klapper et al. 2000; Levkowitz et al.
2000). However, the actual extent of Cbl binding is
debated, and ineYcient binding of Cbl could also explain
the low lysosomal degradation of ErbB2 (Chan et al. 2004;
Dankort et al. 1997; Levkowitz et al. 1996, 2000; Olayioye
et al. 2000).
Several groups have reported that ErbB2 can transfer its
endocytic reluctance to EGFR, since ErbB2 overexpression
protects EGFR from endocytic downregulation and can
increase EGFR levels (Haslekas et al. 2005; Muthuswamy
et al.  1999; Wang et al. 1999; Worthylake et al. 1999).
However, the studies do not reach similar conclusions
regarding the underlying mechanism, and diVerent models
have been presented including lack of Cbl recruitment to
activated EGFR (Muthuswamy et al. 1999), inhibited for-
mation of clathrin coated pits after EGFR stimulation
(Haslekas et al. 2005), or reduced targeting of internalized
EGFR to lysosomes (Worthylake et al. 1999).
Although it is well established that ErbB2 is severely
endocytosis impaired compared to EGFR, there is currently
no consensus model of how this is achieved. Taking into
account the major focus that ErbB2 receive as an oncogene
and as a drug target, a better understanding of the mecha-
nisms hindering ErbB2 endocytosis and lysosomal degra-
dation is warranted.
Endocytic downregulation of ErbB3 and ErbB4
At present, remarkably little is known about endocytosis of
ErbB3 and ErbB4. In the Wrst studies of their endocytosis,
ErbB3 and ErbB4 were reported to be internalization
impaired to the same extent as ErbB2 (Baulida et al. 1996).
In accordance with this, the ErbB3- and ErbB4-speciWc
ligand Heregulin1 was found to be internalized less
eYcient and much slower than the EGFR-speciWc ligand
EGF, supporting that ErbB3 and ErbB4 are not endocyto-
Fig. 3 EGF induces membrane ruZing and macropinocytosis. HEp2
cells expressing GPI-GFP as a marker of the plasma membrane were
followed by 3D confocal microscopy over time. The upper panel
shows two cells that were imaged before and 5 min after stimulation
with 100 ng/ml EGF. Arrows indicate membrane ruZes formed after
EGF stimulation. The lower panel shows that ruZing leads to forma-
tion of macropinosomes (arrows). The large image to the left shows a
cell 7 min after stimulation with 100 ng/ml EGF, and the small images
show a time sequence during which macropinosomes are formed. Bars,
20 mHistochem Cell Biol (2008) 129:563–578 571
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sed as eYciently as EGFR (Baulida and Carpenter 1997;
Waterman et al. 1998). Interestingly, the endocytic impair-
ment of ErbB3 could be transferred to EGFR by replacing
the EGFR C-terminal tail with the ErbB3 C-terminal tail,
suggesting that there are regions in the C-terminus of
ErbB3 that protect the receptor against internalization
(Waterman et al. 1999).
Whereas the abovementioned studies suggest that ErbB3
and ErbB4 are endocytosis impaired, both of the receptors
can be ubiquitinated (Cao et al. 2007; Omerovic et al. 2007;
Qiu and Goldberg 2002). In case of ErbB3, heregulin1
stimulation leads to ubiquitination of the receptor by the
ubiquitin ligase Nrdp1. Knockdown of Nrdp1 increases the
steady-state levels of ErbB3, suggesting that Nrdp1-medi-
ated ubiquitination may target ErbB3 to degradation (Qiu
and Goldberg 2002). ErbB4 is ubiquitinated by the ubiqui-
tin ligase Itch, which induces increased degradation of
ErbB4 when overexpressed (Omerovic et al. 2007). The
ubiquitination-stimulated degradation of both ErbB3 and
ErbB4 depends upon proteasomal activity (Cao et al. 2007;
Omerovic et al. 2007; Qiu and Goldberg 2002). Interest-
ingly, the degradation appears to involve lysosomes as
well, since inhibition of lysosomal function retards the deg-
radation of both ErbB3 and ErbB4 (Cao et al. 2007;
Omerovic et al. 2007). This apparent need for both lyso-
somes and proteasomes for receptor degradation may
appear as a paradox, but it has been shown that proteasomal
activity is required for lysosomal degradation of EGFR as
well (Alwan et al. 2003; Longva et al. 2002). Thus, if this is
also the case for ErbB3 and ErbB4, the block of receptor
degradation seen after proteasomal inhibition could be due
to an eVect on lysosomal function like the one observed for
EGFR. Obviously, this is in discrepancy with the studies
reporting that neither ErbB3 nor ErbB4 becomes eYciently
endocytosed, and more studies are therefore warranted
addressing the role of endocytosis and lysosomal degrada-
tion of ErbB3 and ErbB4, not least in cancer cells.
Escape of endocytic downregulation in cancer
Several EGFR mutants have been found in tumors indicat-
ing an oncogenic role of these mutants. The mutations can
be in the form of small or large deletions, point mutations,
or ampliWcations and these alterations can be found both in
the intra- and extracellular parts of EGFR (Fig. 1). Whether
the mutations are the cause of or a result of transformation
is often not clear, but some EGFR mutants show increased
signaling, which will contribute to oncogenesis. The
increased signaling can be the result of constitutive activa-
tion and/or impaired downregulation. In this review we will
focus on examples of EGFR mutants with impaired down-
regulation.
Proper association of the activated receptor with the
downregulation machinery is essential for stopping the sig-
naling of EGFR. As described above, binding of the ubiqui-
tin ligase Cbl to EGFR is central in the downregulation.
EGFRvIV and EGFRvV are both found in glioblastomas
(Frederick et al. 2000; Peschard and Park 2003; Zandi et al.
2007). Due to intracellular deletions, these mutants lack the
direct binding site of Cbl and in addition EGFRvV also lacks
the indirect Grb2-mediated binding sites (Frederick et al.
2000; Peschard and Park 2003; Zandi et al. 2007). The viral
oncogene v-ErbB resembles EGFR, but lacks certain parts
including the direct binding site of Cbl (Peschard and Park
2003; Zandi et al. 2007). The downregulation of EGFRvIV,
EGFRvV and v-ErbB has not been investigated, but they
would be expected to have an impaired downregulation.
Fig. 4 Crosslinking of ErbB2 induces receptor internalization. a
Fixed SK-BR-3 breast cancer cells have been incubated with a mouse
monoclonal antibody against the extracellular N-terminal part of
ErbB2, and subsequently with a gold-conjugated anti-mouse antibody.
Thereafter the cells were embedded in Epon, sectioned and examined
in the electron microscope. It is seen that ErbB2 is mainly associated
with membrane protrusions. An empty clathrin-coated pit (CCP) is
also seen. b, c SK-BR-3 cells have been incubated for 1 h at 37°C with
the anti-ErbB2 antibody followed by the gold-conjugated antibody be-
fore  Wxation and embedding. Note how the antibody crosslinking
drives ErbB2 down from the protrusions to the bulk membrane, where
it is seen in clathrin-coated pits (CCP). Labeling of a multivesicular
body (MVB) is also seen in c, showing that crosslinked ErbB2 is inter-
nalized. For details see (Hommelgaard et al. 2004). Bar 0.5 m572 Histochem Cell Biol (2008) 129:563–578
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The best characterized EGFR mutant with impaired
downregulation is EGFRvIII. Initially found in glioblas-
tomas (Sugawa et al. 1990), EGFRvIII has later been
found in a range of other types of tumors (Garcia de
Palazzo et al. 1993; Ge et al. 2002; Moscatello et al.
1995; Okamoto et al. 2003; Olapade-Olaopa et al. 2000).
In concordance with this, EGFRvIII can transform Wbro-
blasts and the receptor enhances proliferation and/or
tumorigenicity of cells both in vivo and in vitro (Batra
et al. 1995; Moscatello et al. 1995; Nagane et al. 1996;
Nishikawa et al. 1994; Pedersen et al. 2005a,  2005b;
Tang et al. 2000). EGFRvIII is characterized by a dele-
tion of amino acid residues 6–273 found in the extracellu-
lar part of EGFR. This gives a truncated 145 kDa receptor
with a non-functional ligand binding pocket and no
dimerization arm. Thus, EGFRvIII is incapable of bind-
ing any ligands; the receptor is however constitutively
active (Kuan et al. 2001), and it activates Ras-Erk1/2 and
PI 3-kinase-Akt (Antonyak et al. 1998; Chu et al. 1997;
Montgomery et al. 1995; Moscatello et al. 1996, 1998).
The constitutive activity may be suYcient for tumorige-
nicity, but impaired downregulation would enhance the
eVect. EGFRvIII can associate with overexpressed Cbl
and this leads to downregulation (Davies et al. 2006).
However, two recent reports show that EGFRvIII is not
degraded in cells with endogenous levels of Cbl, and that
this can be due to virtually no phosphorylation of Y1045
(Grandal et al. 2007; Han et al. 2006). In concordance
with the hypophosphorylation at the direct binding site
Y1045, Cbl binds primarily through the adaptor protein
Grb2 (Grandal et al. 2007). This gives no detectable ubiqui-
tination, and instead of being degraded, internalized
EGFRvIII is recycled back to the plasma membrane
(Grandal et al. 2007). Thus, as seen for the Y1045F
EGFR mutant, direct binding of Cbl to the receptor
appears to be necessary for eYcient degradation.
In conclusion, endocytic impairment may be a returning
theme of oncogenic EGFR mutants. ErbB signaling can
also be sustained if the molecular machinery normally
involved in receptor downregulation does not function opti-
mally. Indeed, several mutations of such proteins have been
found in tumors, including Cbl, TSG101 (an ESCRT-I sub-
unit), and VPS25 (an ESCRT-II subunit) (recently
reviewed in (Haglund et al. 2007)).
Endocytic downregulation of ErbB receptors 
as a therapeutic target in cancer treatment
Since lack of endocytic downregulation is an emerging
theme in ErbB cancer biology, it is evident that stimulation
of ErbB endocytosis and lysosomal degradation is an
attractive means to inhibit tumor growth.
Antibody-mediated crosslinking can induce internalization 
of ErbB receptors
From a therapeutic perspective, an appealing way to induce
endocytic downregulation of ErbB receptors is by anti-
body-mediated crosslinking. Indeed, an eYcient way to
induce endocytosis of both EGFR and ErbB2 is crosslink-
ing with polyvalent antibody conjugates (Fig. 4 b, c)
(Friedman et al. 2005; Hommelgaard et al. 2004). The most
studied ErbB2 antibody with an anti-tumor potential is
Trastuzumab, which is currently used in the treatment of
breast cancer (Hudis 2007). Although the dominating opin-
ion has been that Trastuzumab causes endocytic downregu-
lation of ErbB2 (Menard et al. 2003; Rubin and Yarden
2001; Yarden 2001), several recent studies suggest that
Trastuzumab does not induce endocytosis of ErbB2 to a
signiWcant degree (Austin et al. 2004; Hommelgaard et al.
2004; Longva et al. 2005).
Cetuximab is an antibody targeting EGFR that is cur-
rently used in treatment of colorectal cancer and head and
neck cancer (Harari et al. 2007). Several studies have
shown that Cetuximab induces internalization of EGFR
(Jaramillo et al. 2006; Sunada et al. 1986). In contrast to
ligand-induced endocytosis, Cetuximab-induced EGFR
internalization is independent of receptor tyrosine kinase
activity, and it is both slower and less eYcient in terms of
receptor downregulation than the ligand-induced endocyto-
sis (Jaramillo et al. 2006).
At present, the knowledge of mechanisms underlying
antibody-mediated endocytic downregulation is relatively
sparse. It is clear that the endocytic potential of antibodies
vary, but the reason for this remains elusive. Furthermore, it
is debated whether the endocytic potential of antibodies is
correlated to their anti-tumor potential (Hurwitz et al. 1995;
Klapper et al. 1997; Park et al. 1999). Indeed, in cases
where the anti-tumor eVect of therapeutic antibodies is in
part due to antibody-dependent activation of an immune
response, internalization of bound antibodies will be a thera-
peutic disadvantage, since it will clear the surface for anti-
bodies that will otherwise be recognized by immune cells
such as natural killer cells. However, antibody-mediated
receptor endocytosis followed by degradation may be
advantageous in the treatment of tumors that rely heavily
upon ErbB receptor signaling as a growth-promoting signal.
A useful observation is that extensive antibody-based
crosslinking of ErbB receptors is far more eYcient at
inducing ErbB endocytic downregulation than single anti-
bodies are (Friedman et al. 2005; Hommelgaard et al.
2004). Crosslinking can either be done using antibodies
that forms multivalent aggregates via secondary antibodies
or gold particles (Hommelgaard et al. 2004) or by a more
clinically relevant approach using combinations of mono-
clonal antibodies against distinct epitopes in an ErbB recep-Histochem Cell Biol (2008) 129:563–578 573
123
tor (Friedman et al. 2005). Thus, whereas administration of
Trastuzumab alone did not induce signiWcant ErbB2 endo-
cytosis, the combination of Trastuzumab with another
monoclonal antibody to ErbB2 was very eYcient at down-
regulating ErbB2. In addition, the combination of two anti-
bodies was much more eYcient at inhibiting tumor growth
in a mouse model compared to Trastuzumab administered
alone (Friedman et al. 2005).
Hsp90 inhibition stimulates ErbB2 cleavage 
and internalization
Another eYcient way to induce endocytosis and lysosomal
degradation of ErbB2 is inhibition of the chaperone HSP90.
HSP90 has gained a lot of attention due to the involvement
of many of its clients in cancers, and several inhibitors are
being tested in clinical trials, including the Geldanamycin
derivative 17-AAG (Goetz et al. 2003; Solit and Chiosis
2008; Vastag 2006; Whitesell and Lindquist 2005). ErbB2
is one of the most prominent client proteins of the chaper-
one HSP90 (Citri and Yarden 2006; Linggi and Carpenter
2006), and this interaction is considered as a potentially
valuable pharmacological target (Citri et al. 2004; Marmor
et al. 2004; Neckers 2002; Neckers and Ivy 2003). ErbB2
overexpressing cancer cells often binds 17-AAG with an
even higher aYnity than other cancers cells, suggesting that
ErbB2 overexpressing cells are highly dependent on HSP90
activity (Kamal et al. 2003). Inhibition of HSP90, e.g. by
using Geldanamycin, leads to recruitment of the cochaper-
one and ubiquitin ligase CHIP to ErbB2 and ubiquitination
of the receptor (Xu et al. 2002; Zhou et al. 2003).
Several degradation mechanisms are involved in ErbB2
downregulation following its ubiquitination. Mimnaugh
and coworkers (Mimnaugh et al. 1996) found that HSP90-
inhibition led to degradation of ErbB2 in a proteasome-
dependent manner, and this has been interpreted as if degra-
dation of the transmembrane ErbB2 was carried out by the
proteasome (Citri et al. 2002; Hong et al. 1999; Way et al.
2004; Xu et al. 2001; Zheng et al. 2000). However, later
studies found that ErbB2 is endocytosed and degraded in
lysosomes after Geldanamycin stimulation (Fig. 5 a) (Aus-
tin et al. 2004; Lerdrup et al. 2006; Longva et al. 2005; Tik-
homirov and Carpenter 2000), and that the proteasomal
activity is actually needed for endocytosis and lysosomal
degradation of ErbB2 after Geldanamycin stimulation
(Lerdrup et al. 2006). Finally, Tikhomirov and Carpenter
have demonstrated that the C-terminus of ErbB2 is cleaved
by endoproteases into a transmembrane p135 and several
cytosolic fragments in response to Geldanamycin-treatment
(Tikhomirov and Carpenter 2000,  2001,  2003). Recent
work from our group showed that this cleavage also pro-
motes endocytosis and lysosomal degradation of ErbB2
(Lerdrup et al. 2007). Using a doubly Xuorescent ErbB2
tagged with yellow Xuorescent protein (YFP) and cyan
Xuorescent protein (CFP) in each terminus, we found that
ErbB2 was cleaved at the plasma membrane after Geldana-
mycin stimulation. C-terminally cleaved ErbB2 as well as
an ErbB2 deletion mutant lacking its C-terminal tail were
endocytosed and degraded in lysosomes far more eYciently
than full length ErbB2 (Fig. 5b) (Lerdrup et al. 2007).
As opposed to ErbB2, wild-type EGFR is relatively
insensitive to Hsp90 inhibition. However, the Geldanamy-
cin derivative 17-AAG stimulates degradation of constitu-
tively active EGFR mutants commonly found in lung
cancer (Sawai et al. 2008). Whether 17-AAG induces deg-
Fig. 5 HSP90 inhibition stimulates ErbB2 cleavage and internaliza-
tion. a ErbB2 is internalized after 2 h of Geldanamycin-stimulation
(3 M) of SK-BR-3 breast cancer cells. Sequential immunocytochem-
istry was used to distinguish between internalized and surface associ-
ated ErbB2. Fixed cells were stained with antibodies against ErbB2
before permeabilization (green). After permeabilization, cells were
once again stained with antibodies against ErbB2 (red). Only the latter
antibody staining (red) gain access to intracellular ErbB2, which there-
fore appears red whereas surface ErbB2 is stained both red and green
and therefore appears yellow. For details see (Lerdrup et al. 2006). b
YFP-ErbB2-CFP is cleaved after 2 h of Geldanamycin-stimulation of
SK-BR-3 cells. A construct with YFP fused to the extracellular N-ter-
minus and CFP fused to the intracellular C-terminus of ErbB2 was ex-
pressed in SK-BR-3 cells for 48 h and followed by incubation with
0.3 M Geldanamycin for 2 h as indicated. YFP-ErbB2-CFP where the
C-terminal tail has been cleaved oV appears green. Note the increased
amount of such cleavage in vesicles compared to the plasma membrane
after Geldanamycin stimulation. For details see (Lerdrup et al. 2007).
Bars 20 m574 Histochem Cell Biol (2008) 129:563–578
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radation of mutant EGFRs by stimulating endocytosis and
lysosomal degradation remains to be determined.
Perspectives
In spite of its crucial importance both in health and disease,
the ErbB receptor system still has hidden secrets regarding
its regulation. It is evident that we need to know much more
about the molecular mechanisms underlying endocytic
downregulation of the otherwise heavily investigated ErbB
receptors. One important area that deserves future attention
is further mapping of the mechanisms responsible for
recruitment of EGFR to CCPs. Moreover, EGFR endocyto-
sis does not seem to be representative of the other ErbB
receptor family members, which all appear to be endocyto-
sis impaired to some extent compared to EGFR. It is espe-
cially of interest to decipher how formation of heterodimers
between the diVerent ErbB receptors aVects their endocytic
downregulation. In addition, the large number of ErbB
ligands adds further complexity to the system, since they
may vary in the capability to stimulate endocytosis and
lysosomal degradation of their receptors. Interestingly, the
few ligands that have been investigated so far diVer signiW-
cantly in their ability to induce endocytic downregulation
of ErbB receptors.
More insight into endocytic downregulation of ErbB
receptors is indeed relevant for understanding the role of
these receptors in cancer, and it could lead to identiWcation
of novel targets for cancer therapy directed at downregulating
signaling receptors. Although still in the making, the
clinical as well as preclinical results show that targeted
therapy stimulating endocytic downregulating of ErbB
receptors is a promising tool in cancer treatment.
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